BIOCEO15: New Report On Biotech Venture Capital Over Last 10 Years Finds Heavy Focus on R&D
Published: Feb 10, 2015
February 10, 2015
By Riley McDermid, and and Mark Terry, BioSpace.com Breaking News Staff
Three times more venture capital dollars were spent on drug improvements than on new drugs in the last decade, found a study published yesterday by the Biotechnology Industry Organization (BIO), but VCs are increasingly interested in rare diseases and shying away from Series A rounds.
The first-of-its-kind study covers a 10-year-period from 2004 to 2013 and set out to “better understand investor trends in order to determine where scientific or policy issues may be impacting the ability to maintain a robust pipeline of innovative medicines.”
The study was released by the BIO Industry Analysis team at the 2015 BIO CEO & Investor Conference being held in New York City the last two days, Feb. 9 and 10.
“Since venture financing is the lifeblood of our industry, we wanted to better understand trends in venture financing over the last decade by conducting the broadest, most comprehensive study possible,” said Cartier Esham, executive vice president of Emerging Companies in a statement. “The aim was to identify funding trends for emerging drug developers within specific therapeutic areas and across varying levels of innovation.”
The report draws on data from four venture capital databases, including Thomson Reuters, BioCentury, Elsevier and Evaluate Pharma. It evaluates 1,200 U.S. drug companies that received more than 2,000 rounds of funding over a 10-year period totaling over $38 billion.
It found that VCs have turned their focus in recent years to specialty and rare-disease medicines, often because they carry enormous price tags but are so crucial to patient health that insurers have no alternatives but the pay for them. That leaves investors in prime financial condition.
"VCs will pull back from areas that are seen as having unfavorable or unpredictable regulatory and reimbursement hurdles," the BIO report said. "This has had some impact on tilting investment over the last few years toward drug R&D for small populations and rare diseases."
Novel science is also raring back, with biologic now getting 50 percent of VC funding, though less money is being put into novel drug research. That is particularly true in areas with massive public health issues, such as diabetes and gastrointestinal, respiratory, and cardiovascular conditions. Instead, rare diseases remain a focus, because VCs have a track record of remaining patient in order to have a large payout when a company exits—something Big Pharma has long struggled to come to terms with.
"We see significant interest in rare diseases as gene therapy technologies mature and generate meaningful clinical data and returns for investors," Soffinova Ventures partner Jim Healy said in the BIO report.
The study, titled, “Venture Funding of Therapeutic Innovation: A Comprehensive Look at a Decade of Venture Funding of Drug R&D” is authored by David Thomas and Chad Wessel. Thomas is Director of Industry Research & Analysis for BIO and Wessel is Manager. The report provides detailed analysis of various aspects of funding and research, including breakdowns by diseases/organ type, such as diabetes, psychiatry, gastrointestinal and cardiovascular, as well as by funding type.
Additional findings are that in 10 years, 78 percent of U.S. venture funds for therapeutics were spent on novel drug research and development. Despite the funding, there was a 21 percent drop from the five-year period of 2004 to 2008 and the five-year period from 2009 to 2013, sharply marked into two distinct halves by the financial crisis of 2008 and 2009. As previously reported by BioSpace, there are fewer first-time Series A financing rounds recently, dropping by 30 percent from a high in 2006.
The report examines broad categories of venture capital investment, noting trends and digging into causes.
“The JOBS Act, signed in 2012, has been a key factor in opening capital markets to small innovative biotech companies,” said Jonathan Leff, a partner in Deerfield Management in the report. “The increased access to public markets has already started a favorable feedback effect of capital flowing back into private start-up companies.”
BioSpace Temperature Poll
Who Do You Think Will Be Sanofi’s New CEO? French drugmaker Sanofi said Thursday that it will name a new chief executive in mere weeks, as it attempted to put to rest rumors that the company could not find any executives willing to take the reins after it unceremoniously ousted its previous CEO last fall. Who do you think will soon be crowned king? BioSpace wants your opinion!